A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis
Not available.
Saved in:
Main Authors: | Sargam Rachit Vohra, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol J. Whelan, Philip N. Hawkins, Julian Gillmore, Helen J. Lachmann, Shameem Mahmood, Ashutosh D. Wechalekar |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-07-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/12153 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis
by: Muhammad Umaid Rauf, et al.
Published: (2025-06-01) -
The role of pomalidomide in treatment of relapse and refractory multiple myeloma
by: S. V. Voloshin, et al.
Published: (2022-01-01) -
Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report
by: Yu. E. Ryabukhina, et al.
Published: (2023-12-01) -
Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01) -
Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)